BsUFA III Talks Begin With Regulatory Science Disagreement

 
• By Derrick Gingery

Brand trade group negotiators don’t support a biosimilar regulatory science proposal from the biosimilar and generic drug trade groups.

Anti-recessionary injection (vaccination) by hundred dollar denomination close up on a black background
Negotiations to extend BsUFA another five years began in March. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics